糖尿病视网膜病变(diabetic retinopathy，DR)是糖尿病最常见、最典型的微血管并发症之一，也是我国成人失明或严重视力丧失的主要原因。目前关于DR的治疗主要包括药物治疗、激光治疗以及手术治疗，但这些治疗多为侵入性、破坏性的治疗，且不良反应多，因此寻找新的治疗靶点成为防治DR的热点。微小RNA(microRAN，miRNA)是理想的生物标志物，在细胞凋亡、炎症、氧化应激、病理性新生血管的形成中起到重要的调控作用，有望成为治疗DR的生物学标志物，文章总结了miRNA在DR治疗中的最新研究进展，为DR的临床防治提供新的思路。 Diabetic retinopathy (DR) is one of the most common and typical microvascular complications of diabetes mellitus, and it is also the main cause of blindness or severe visual loss in adults in China. At present, the treatment of DR mainly includes drug therapy, laser therapy and surgical treatment, but most of these treatments are invasive and destructive, and have many adverse reactions. Therefore, finding new therapeutic targets has become a hot spot in the prevention and treatment of DR. MicroRNA(miRNA) is an ideal biomarker, which plays an important regulatory role in apoptosis, inflammation, oxidative stress and pathological neovascularization, and is expected to become a biomarker for the treatment of DR. This article summarizes the latest research progress of miRNA in the treatment of DR, and provides new ideas for the clinical prevention and treatment of DR.
Abstract
Diabetic retinopathy (DR) is one of the most common and typical microvascular complications of diabetes mellitus, and it is also the main cause of blindness or severe visual loss in adults in China. At present, the treatment of DR mainly includes drug therapy, laser therapy and surgical treatment, but most of these treatments are invasive and destructive, and have many adverse reactions. Therefore, finding new therapeutic targets has become a hot spot in the prevention and treatment of DR. MicroRNA(miRNA) is an ideal biomarker, which plays an important regulatory role in apoptosis, inflammation, oxidative stress and pathological neovascularization, and is expected to become a biomarker for the treatment of DR. This article summarizes the latest research progress of miRNA in the treatment of DR, and provides new ideas for the clinical prevention and treatment of DR.
万方数据